Skip to navigation

Mocetinostat (MGCD103)

Indications: Solid Tumors and NSCLC
Drug Candidate: Mocetinostat (MGCD103)

Mirati Therapeutics is enrolling a Phase 1/2 study evaluating the effects of Mocetinostat (MGCD103), a class I HDAC (histone deacetylase) inhibitor, in combination with the AstraZeneca/MedImmune anti-PD-L1 blocking mAb, in patients with Non-Small Cell Lung Cancer (NSCLC). This trial is exploring the potential of mocetinostat to enhance the effectiveness of checkpoint inhibitors in patients with NSCLC.

Find an Active Trial